Dr. Reddy’s Q1 FY08 revenues stood at Rs 1201.8 crore vs Rs 1404.9 crore (Cons, US GAAP)and net profit stood at Rs 182.5 crore vs Rs 139.8 crore. Forex gains were of Rs 28.5 crore vs loss of Rs 7.4 crore. Revenues from international market is at Rs 940 crore vs Rs 1,170 crore. The Q1 Revenues from Betapharm are at Rs 210 crore vs Rs 190 crore. Revenues from Zofran is at Rs 6.6 crore.As per INSIGHT May 2007, betapharm recorded a 36% growth in pharmacy volumes.

Revenues from Allegra stood at Rs 51.7 crore. Market share was at 25%. Dr Reddy's Labs has filed 8 ANDAs including 3 which it was first to file.

Revenues in the API business increased by 13% to Rs 260 crores ($ 64 mln) in Q1 FY08 from Rs 230 crores ($ 57 mln) in Q1 FY07 primarily driven by growth in international markets. Revenues from custom pharmaceuticals services declined to Rs 100 crores ($ 25 mln) in Q1 FY08 from Rs 140 crore ($ 35 mln) in Q1 FY07. This decrease was due to the decline in revenues from Mexico resulting from supply shortages of one of the key raw materials.

Sale of Zofran has been affected by adjustment of Retail inventory. Zofran's exclusivity sales are Rs 6.6 crore on account of self stock adjustment. Dr Reddy's getting into private label in to OTC and is expecting the EPS to be EPS in the 1st year. Private OTC label is expected to Contribute $ 25 million to topline this year. CPS business impacted on account of lack of raw material availability in Mexico.